Tsumura & Co. (TYO:4540)
3,803.00
+32.00 (0.85%)
Aug 25, 2026, 2:44 PM JST
Tsumura & Co. Revenue
Tsumura & Co. had revenue of 49.70B JPY in the quarter ending June 30, 2026, with 15.34% growth. This brings the company's revenue in the last twelve months to 199.23B, up 10.38% year-over-year. In the fiscal year ending March 31, 2026, Tsumura & Co. had annual revenue of 192.62B with 6.36% growth.
Revenue (ttm)
199.23B
Revenue Growth
+10.38%
P/S Ratio
1.41
Revenue / Employee
40.47M
Employees
4,923
Market Cap
281.11B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 192.62B | 11.52B | 6.36% |
| Mar 31, 2025 | 181.09B | 30.25B | 20.05% |
| Mar 31, 2024 | 150.85B | 10.80B | 7.71% |
| Mar 31, 2023 | 140.04B | 10.50B | 8.10% |
| Mar 31, 2022 | 129.55B | -1.34B | -1.02% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eisai | 857.06B |
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Nippon Shinyaku | 180.29B |
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
| Kissei Pharmaceutical | 98.60B |